Regeneron shares are up 41% in six months as FDA approvals, strong Dupixent profits and oncology gains lift investor confidence.

Panelists discuss how real-world adherence to loading doses and thoughtful switching or reloading strategies can optimize ...

Shanghai Henlius Biotech, Inc. Class H ( ($HK:2696) ) has shared an update. Shanghai Henlius Biotech has initiated a first-in-human phase 1 ...

LAHORE: Artificial intelligence (AI) is enabling researchers to uncover new cancer applications for widely used medicines by ...

NovaBridge Also Included in the Highly Regarded Nasdaq Biotech Index, Emphasizing its Position as an Industry Leader Opening ...

Corcept sought FDA approval despite finding relacorilant was statistically no better than placebo in one of two Phase III ...

An overview of the top 10 stories from Optometry Times in 2025.

The FDA issued a third complete response letter for ONS-5010/Lytenava, requesting confirmatory efficacy evidence for wet AMD treatment. Lytenava is an ophthalmic bevacizumab formulation, potentially ...

ASCO GU 2025 had groundbreaking advancements in genitourinary cancer treatments, focusing on prostate cancer, renal cell ...

Symptoms of stage 3 RCC vary; some patients experience blood in the urine, flank pain, fatigue, weight loss, or a palpable abdominal mass, whereas others are diagnosed incidentally during imaging for ...

India is not only the “diabetes capital” of the world but is also fast emerging as the “diabetic retinopathy capital,” experts warned, while attribut ...